Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Pierre SquiffletEverardo Delforge SaadSibylle LoiblMarion T van MackelenberghMichael UntchPriya RastogiLuca GianniAndreas SchneeweißPierFranco ConteMartine J PiccartHervé R BonnefoiChristian JackischValentina NekljudovaGong TangPinuccia ValagussaColin NeateRichard D GelberCoralie PoncetDominik HeinzmannCarsten DenkertCharles E GeyerJavier CortesValentina GuarneriEvandro de AzambujaDavid A CameronGustavo IsmaelNorman WolmarkPatricia CortazarMarc E Buysenull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Although pCR may be useful for patient management, it cannot be considered as a surrogate for EFS or OS in neoadjuvant trials of HER2-positive, operable breast cancer.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- locally advanced
- rectal cancer
- early breast cancer
- lymph node
- induced pluripotent stem cells
- neoadjuvant chemotherapy
- squamous cell carcinoma
- pluripotent stem cells
- case report
- radiation therapy
- stem cells
- mesenchymal stem cells
- bone marrow